The Brigham and Women's Hospital, Inc.

The General Hospital Corporation

Beth Israel Deaconess Medical Center, Inc.

Bloodcenter Research Foundation

Po-Shun Lee

Thomas P Stossel

Ravi Thadhani

Ananth Karumanchi

Jane Yu

Katarzyna Maresz

Yang Sun

Bonnie Dittel

Stossel Thomas P P

Thadhani Ravi

The invention is directed, in part, to the use of gelsolin to diagnose, monitor, and treat subjects with renal failure (e.g., chronic renal failure subjects on dialysis).

Diagnostic and therapeutic uses of gelsolin in renal failure

The invention relates to the use of gelsolin to treat infections and to monitor the treatment of infections. The invention also provides methods up-regulating interleukin expression and methods for down-regulating pro-inflammatory cytokine expression.

Use of gelsolin to treat infections

The present invention relates to methods of treating a condition associated with mTORC1 hyperactivation or TSC2-deficient cancer, the method comprising administering to a subject having the cancer a pharmaceutically-effective amount of a poly(ADP-ribose) polymerase 1 (PARP1) inhibitor. In some embodiments, the condition associated with mTORC1 hyperactivation is tuberous sclerosis complex (TSC). In some embodiments, the condition associated with mTORC1 hyperactivation is lymphangioleiomyomatosis (LAM). In some embodiments, the condition associated with mTORC1 hyperactivation is TSC2-deficient cancer.

Targeting PARP1 for treatment of TSC and cancers

The invention relates to the use of gelsolin to treat neurologic diseases (e.g., multiple sclerosis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of neurologic diseases.

Use of gelsolin to treat multiple sclerosis and to diagnose neurologic disease (stossel)

Growing community of inventors

Brookline, MA, United States of America

Po-Shun Lee